Search

Our research focuses on two main areas: hyperpolarized 13C, 15N, 89Y and 107, 109Ag compounds, and conventional lanthanide-based T1 shortening and paraCEST imaging agents.

Our laboratory actively studies disease processes that disrupt normal metabolism.

We investigate novel, EHR integrated strategies to advise clinicians on risk of adverse outcomes among patients with diabetic cardiomyopathy.

Active and Inactive Grants for the Cardiometabolic Research Unit

Alumni members of the Cardiometabolic Research Unit

Skip to main content Awards NIH (F31) Award Jordan Wall (2024) American Aging Association (AGE) Early Career Scholar Rene Solano Fonseca (2023) Glenn Foundation Diversity Scholarship Lexus Tatge (2022) Spring GSO Travel Award Abigail Watterson (2022) O'Donnell Brain Institute Neural Scientist Trainin…

Our lab has ongoing research within cardiovascular disease registries and administrative claims databases such as the AHA-Get With The Guidelines-Heart Failure program and CMS Medicare data, to study the impact of care provided during in-hospital and outpatient clinical encounters on long-term outcomes among patients with cardiovascular diseases such as heart failure.

Lab news including events, conferences, publications, and accomplishments of the CMRU.

The ultimate goal of the Kittler Lab's research is to develop novel therapeutic approaches that target transcription factors, which play important roles in common solid tumors (brain, breast, lung and prostate cancer) and could therefore have translational potential.

The Kraus Lab is interested in the basic mechanisms of nuclear signaling and gene regulation by small molecules and how these signaling pathways relate to human physiology and disease states.